<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001067</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 298</org_study_id>
    <secondary_id>11274</secondary_id>
    <nct_id>NCT00001067</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs</brief_title>
  <official_title>A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine drug efficacy and safety in HIV-infected patients treated with zidovudine ( AZT&#xD;
      ) versus stavudine ( d4T ) versus both drugs. Also, to compare short- and long-term changes&#xD;
      in magnitude of HIV RNA over time.&#xD;
&#xD;
      Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of&#xD;
      the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV&#xD;
      activity in previous studies, provides an additional therapeutic option.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of&#xD;
      the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV&#xD;
      activity in previous studies, provides an additional therapeutic option.&#xD;
&#xD;
      Patients are randomized to receive d4T alone, AZT alone, or both in combination for at least&#xD;
      12 weeks. After week 12, 3TC is added to the combination arm. Treatment continues for up to&#xD;
      48 weeks (was a total of 48 weeks, amended 3/26/96).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">November 1997</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>105</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  TMP / SMX, aerosolized pentamidine, or dapsone for PCP prophylaxis.&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Atovaquone.&#xD;
&#xD;
          -  IV pentamidine.&#xD;
&#xD;
          -  TMP / SMX.&#xD;
&#xD;
          -  Trimetrexate.&#xD;
&#xD;
          -  Trimethoprim-dapsone.&#xD;
&#xD;
          -  Clindamycin-primaquine.&#xD;
&#xD;
          -  Topical antifungals.&#xD;
&#xD;
          -  Clotrimazole.&#xD;
&#xD;
          -  Ketoconazole.&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Itraconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Isoniazid.&#xD;
&#xD;
          -  Pyrazinamide.&#xD;
&#xD;
          -  Clofazimine.&#xD;
&#xD;
          -  Clarithromycin.&#xD;
&#xD;
          -  Azithromycin.&#xD;
&#xD;
          -  Ethambutol.&#xD;
&#xD;
          -  Amikacin.&#xD;
&#xD;
          -  Ciprofloxacin.&#xD;
&#xD;
          -  Ofloxacin.&#xD;
&#xD;
          -  Pyrimethamine.&#xD;
&#xD;
          -  Sulfadiazine.&#xD;
&#xD;
          -  Clindamycin.&#xD;
&#xD;
          -  Filgrastim ( G-CSF ).&#xD;
&#xD;
          -  Up to 1000 mg/day acyclovir.&#xD;
&#xD;
          -  Erythropoietin.&#xD;
&#xD;
          -  Antibiotics.&#xD;
&#xD;
          -  Antipyretics.&#xD;
&#xD;
          -  Analgesics.&#xD;
&#xD;
          -  Antiemetics.&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Local radiation therapy.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  CD4 count 300 - 600 cells/mm3.&#xD;
&#xD;
          -  NO history of AIDS.&#xD;
&#xD;
          -  NO active opportunistic infection.&#xD;
&#xD;
          -  NO prior nucleoside therapy.&#xD;
&#xD;
          -  Life expectancy at least 2 years.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Serious underlying medical condition other than HIV such that life expectancy is less&#xD;
             than 2 years.&#xD;
&#xD;
          -  Malignancy requiring systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Active grade 2 or worse peripheral neuropathy.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretrovirals other than study drugs.&#xD;
&#xD;
          -  Systemic cytotoxic chemotherapy.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
        Patients with the following prior conditions are excluded:&#xD;
&#xD;
          -  Chronic diarrhea defined as three or more stools per day for 15 days, within 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Unexplained temperature &gt;= 38.5 C for any 7 days within 30 days prior to study entry.&#xD;
&#xD;
          -  Active participation in other experimental therapy within 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior nucleoside antiretrovirals of 1 week or longer duration.&#xD;
&#xD;
          -  Any antiretroviral within 90 days prior to study entry.&#xD;
&#xD;
          -  Non-nucleoside reverse transcriptase inhibitors and protease inhibitors within 30 days&#xD;
             prior to study entry.&#xD;
&#xD;
          -  Biologic response modifiers such as IL-2 and interferon within 30 days prior to study&#xD;
             entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Havlir D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Pollard R</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Richman D</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Friedland G</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard University Hosp., Div. of Infectious Diseases, ACTU</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Ctr. CRS</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State Univ. AIDS CRS</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puerto Rico-AIDS CRS</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cadman J. 2, 4, 6, 8, who's afraid to phosphorylate? GMHC Treat Issues. 1998 Feb;12(2):6-8.</citation>
    <PMID>11365218</PMID>
  </reference>
  <reference>
    <citation>Havlir DV, Friedland G, Pollard R, Tierney C, Smeaton L, Fox L, Richman DD. Combination zidovudine (ZDV) and stavudine (d4T) therapy versus other nucleosides: report of two randomized trials (ACTG 290 and 298). Conf Retroviruses Opportunistic Infect. 1998 Feb 1-5;5th:79 (abstract no 2)</citation>
  </reference>
  <reference>
    <citation>Pollard RB, Tierney C, Havlir D, Tebas P, Fox L, Smeaton L, Richman D, Friedland GH. A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with &gt;300 CD4 cells who were antiretroviral naive (ACTG 298). AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):699-704. doi: 10.1089/088922202760072311.</citation>
    <PMID>12167276</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Stavudine</keyword>
  <keyword>Lamivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

